Search

Your search keyword '"Dawson Nancy A"' showing total 582 results
Start Over Author "Dawson Nancy A"
582 results on '"Dawson Nancy A"'

151. Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (mUC): Primary analysis of IMvigor210 cohort 1.

Author

Balar, Arjun Vasant, primary, Galsky, Matt D., additional, Loriot, Yohann, additional, Dawson, Nancy Ann, additional, Necchi, Andrea, additional, Srinivas, Sandy, additional, Joseph, Richard Wayne, additional, Vaishampayan, Ulka N., additional, Sridhar, Srikala S., additional, Quinn, David I., additional, Drakaki, Alexandra, additional, Duran, Ignacio, additional, Rosenberg, Jonathan E., additional, Powles, Thomas, additional, Hoffman-Censits, Jean H., additional, Cui, Na, additional, Mariathasan, Sanjeev, additional, Thastrom, Ann Christine, additional, Abidoye, Oyewale O., additional, and Bajorin, Dean F., additional

Published
2016
Full Text
View/download PDF

153. Pembrolizumab (pembro) plus ipilimumab (ipi) or pegylated interferon alfa-2b (PEG-IFN) for advanced melanoma or renal cell carcinoma (RCC).

Author

Atkins, Michael B., primary, Hodi, F. Stephen, additional, Thompson, John A., additional, McDermott, David F., additional, Hwu, Wen-Jen, additional, Lawrence, Donald P., additional, Dawson, Nancy Ann, additional, Wong, Deborah Jean Lee, additional, Bhatia, Shailender, additional, James, Marihella, additional, Shu, Xinxin, additional, Perini, Rodolfo F., additional, Ibrahim, Nageatte, additional, Ribas, Antoni, additional, and Choueiri, Toni K., additional

Published
2016
Full Text
View/download PDF

156. Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancer

Author

Madan, Ravi A., primary, Karzai, Fatima H., additional, Ning, Yang-Min, additional, Adesunloye, Bamidele A., additional, Huang, Xuan, additional, Harold, Nancy, additional, Couvillon, Anna, additional, Chun, Guinevere, additional, Cordes, Lisa, additional, Sissung, Tristan, additional, Beedie, Shaunna L., additional, Dawson, Nancy A., additional, Theoret, Marc R., additional, McLeod, David G., additional, Rosner, Inger, additional, Trepel, Jane B., additional, Lee, Min-Jung, additional, Tomita, Yusuke, additional, Lee, Sunmin, additional, Chen, Clara, additional, Steinberg, Seth M., additional, Arlen, Philip M., additional, Gulley, James L., additional, Figg, William D., additional, and Dahut, William L., additional

Published
2016
Full Text
View/download PDF

159. Comparison of survival of African-American (AA) patients (pts) in docetaxel (D)-based combination therapies in metastatic castrate-resistant prostate cancer (mCRPC).

Author

Karzai, Fatima, primary, Madan, Ravi Amrit, additional, Ning, Yang-Min, additional, Theoret, Marc Robert, additional, Arlen, Philip M., additional, Parnes, Howard L., additional, Ojemuyiwa, Michelle A., additional, Strauss, Julius, additional, Dawson, Nancy Ann, additional, McLeod, David G., additional, Harold, Nancy, additional, Couvillon, Anna, additional, Cordes, Lisa M, additional, Chen, Clara, additional, Steinberg, Seth M., additional, Sissung, Tristan M., additional, Price, Douglas K., additional, Gulley, James L., additional, Figg, William Douglas, additional, and Dahut, William L., additional

Published
2016
Full Text
View/download PDF

160. Patient portal use and hospital outcomes.

Author

Dumitrascu, Adrian G., Burton, M. Caroline, Dawson, Nancy L., Thomas, Colleen S., Nordan, Lisa M., Greig, Hope E., Aljabri, Duaa I., and Naessens, James M.

Abstract

Objectives: To determine whether use of a patient portal during hospitalization is associated with improvement in hospital outcomes, 30-day readmissions, inpatient mortality, and 30-day mortality.Materials and Methods: We performed a retrospective propensity score-matched study that included all adult patients admitted to Mayo Clinic Hospital in Jacksonville, Florida, from August 1, 2012, to July 31, 2014, who had signed up for a patient portal account prior to hospitalization (N = 7538).Results: Out of the admitted patients with a portal account, 1566 (20.8%) accessed the portal while in the hospital. Compared to patients who did not access the portal, patients who accessed the portal were younger (58.8 years vs 62.3 years), had fewer elective admissions (54.2% vs 64.1%), were more frequently admitted to medical services (45.8% vs 35.2%), and were more likely to have liver disease (21.9% vs 12.9%) and higher disease severity scores (0.653 vs 0.456). After propensity score matching, there was no statistically significant difference between the 2 cohorts with respect to 30-day readmission (P = .13), inpatient mortality (P = .82), or 30-day mortality (P = .082).Conclusion: Use of the patient portal in the inpatient setting may not improve hospital outcomes. Future research should examine the association of portal use with more immediate inpatient health outcomes such as patient experience, patient engagement, medication reconciliation, and prevention of adverse events. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

161. Opioid Use in Patients with Congestive Heart Failure.

Author

Dawson, Nancy L., Roth, Victoria, Hodge, David O., Vargas, Emily R., and Burton, M. Caroline

Subjects
*THERAPEUTIC use of narcotics, *ACADEMIC medical centers, *CONFIDENCE intervals, *DRUGS, *HEART failure, *LENGTH of stay in hospitals, *COMORBIDITY, *DISCHARGE planning, *TREATMENT effectiveness, *RETROSPECTIVE studies, *PATIENT readmissions, *ODDS ratio, *DIAGNOSIS
Abstract

Objective. To understand the relationship between opioid use in patients with congestive heart failure and outcomes, we compared length of stay (LOS), 30-day readmission rates and 30- and 90-day mortality in patients discharged with a primary diagnosis of congestive heart failure (CHF) who were taking opioids. Design. Retrospective study design. Setting. Patients were seen at a 320-bed academic hospital. Subjects. All patients not awaiting transplant who were discharged with a primary diagnosis of heart failure from January 1, 2011, through December 31, 2014. Methods. Records were reviewed for demographic data, comorbidities and opioid status at admission or discharge. The association of opioid use (at admission and discharge) with LOS, 30-day readmission, and 30 and 90-day mortality was examined. Results. Six hundred eighty-two patients with a principle diagnosis of heart failure were admitted during the study period, with 168 (24.6%) taking opioids at admission. Opioid use at admission was not significantly associated with 30-day readmission (odds ratio [OR] 5 1.24, 95% confidence interval [CI] 5 0.80-1.93), 30-day mortality (hazard ratio [HR] 5 0.91, 95% CI50.47-1.78), 90-day mortality (HR50.95, 95% CI50.58-1.54), or LOS (parameter estimate520.21, 95% CI520.91 to 0.48). One hundred ninety-three patients (28.3%) were prescribed opioids at discharge. No significant differences were observed between those who were and were not taking opioids at discharge for 30-day readmission (OR51.10, 95% CI50.72-1.69) or for 30- or 90-day mortality (HR50.51, 95% CI50.24-1.06 and HR50.67, 95% CI50.41-1.10, respectively). LOS was slightly shorter for patients not using opioids at discharge than for those who were (mean 5 3.8 vs 4.6 days, respectively). Conclusions. Opioid use at admission or discharge in patients with CHF did not appear to affect outcomes. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

165. Overcoming resistance mechanisms in a study of cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).

Author

Karzai, Fatima, primary, Madan, Ravi Amrit, additional, Theoret, Marc Robert, additional, Arlen, Philip M., additional, Strauss, Julius, additional, Chun, Guinevere, additional, Couvillon, Anna, additional, Harold, Nancy, additional, Chen, Clara, additional, Dawson, Nancy Ann, additional, Apolo, Andrea Borghese, additional, Steinberg, Seth M., additional, Trepel, Jane B., additional, Wright, John Joseph, additional, Price, Douglas K., additional, Gulley, James L., additional, Figg, William Douglas, additional, and Dahut, William L., additional

Published
2015
Full Text
View/download PDF

166. Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer (mCRPC).

Author

Monk, Paul, primary, Liu, Glenn, additional, Stadler, Walter Michael, additional, Geyer, Susan Michelle, additional, Sexton, Jennifer L., additional, Wright, John Joseph, additional, Villalona-Calero, Miguel Angel, additional, Wade, James Lloyd, additional, Szmulewitz, Russell Zelig, additional, Gupta, Shilpa, additional, Mortazavi, Amir, additional, Dreicer, Robert, additional, Pili, Roberto, additional, Cooney, Matthew M., additional, Dawson, Nancy Ann, additional, George, Saby, additional, and Garcia, Jorge A., additional

Published
2015
Full Text
View/download PDF

167. Cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).

Author

Karzai, Fatima, primary, Madan, Ravi Amrit, additional, Theoret, Marc Robert, additional, Arlen, Philip M., additional, Dawson, Nancy Ann, additional, Rosner, Inger L., additional, McLeod, David G., additional, Wright, John Joseph, additional, Cordes, Lisa M, additional, Couvillon, Anna, additional, Chun, Guinevere, additional, Harold, Nancy, additional, Steinberg, Seth M., additional, Trepel, Jane B., additional, Price, Douglas K., additional, Gulley, James L., additional, Figg, William Douglas, additional, and Dahut, William L., additional

Published
2015
Full Text
View/download PDF

169. Comparing performance of 30-day readmission risk classifiers among hospitalized primary care patients.

Author

Garrison, Gregory M., Robelia, Paul M., Pecina, Jennifer L., and Dawson, Nancy L.

Subjects
ALGORITHMS, COMPARATIVE studies, DEATH, HOSPITAL patients, PRIMARY health care, RISK assessment, LOGISTIC regression analysis, RECEIVER operating characteristic curves, PATIENT readmissions, DESCRIPTIVE statistics
Abstract

Rationale, aims and objectives Hospital readmission within 30 days of discharge occurs in almost 20% of US Medicare patients and may be a marker of poor quality inpatient care, ineffective hospital to home transitions, or disease severity. Within a patient centered medical home, care transition interventions may only be practical from cost and staffing perspectives if targeted at patients with the greatest risk of readmission. Various scoring algorithms attempt to predict patients at risk for 30-day readmission, but head-to-head comparison of performance is lacking. Compare published scoring algorithms which use generally available electronic medical record data on the same set of hospitalized primary care patients. Methods The LACE index, the LACE+ index, the HOSPITAL score, and the readmission risk score were computed on a consecutive cohort of 26,278 hospital admissions. Classifier performance was assessed by plotting receiver operating characteristic curves comparing the computed score with the actual outcome of death or readmission within 30 days. Statistical significance of differences in performance was assessed using bootstrapping techniques. Results Correct readmission classification on this cohort was moderate with the following c-statistics: Readmission risk score 0.666; LACE 0.680; LACE+ 0.662; and HOSPITAL 0.675. There was no statistically significant difference in performance between classifiers. Conclusions Logistic regression based classifiers yield only moderate performance when utilized to predict 30-day readmissions. The task is difficult due to the variety of underlying causes for readmission, nonlinearity, and the arbitrary time period of concern. More sophisticated classification techniques may be necessary to increase performance and allow patient centered medical homes to effectively focus efforts to reduce readmissions. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

170. Assessment of Real-World Central Nervous System Events in Patients with Advanced Prostate Cancer Using Abiraterone Acetate, Bicalutamide, Enzalutamide, or Chemotherapy.

Author

Pilon, Dominic, Behl, Ajay S., Ellis, Lorie A., Robitaille, Marie-Noëlle, Lefebvre, Patrick, and Dawson, Nancy A.

Abstract

BACKGROUND: Central nervous system (CNS) events are frequently reported among patients with advanced prostate cancer as a consequence of the treatments used in this patient population. OBJECTIVE: To assess the incidence of CNS events in patients with advanced prostate cancer who initiated treatment with abiraterone acetate, bicalutamide, enzalutamide, or chemotherapy. METHODS: The Truven Health MarketScan Research databases were used to retrospectively identify patients with prostate cancer who initiated treatment with abiraterone acetate, enzalutamide, bicalutamide, or chemotherapy after September 1, 2012 (ie, the index date). The chemotherapy agents included cabazitaxel, docetaxel, mitoxantrone hydrochloride, and estramustine, and were used as monotherapy or as combination therapy. Patients were followed until December 31, 2014, the end of exposure to treatment, or until loss to follow-up. Kaplan-Meier rates and adjusted Cox proportional hazard models were used to compare the incidence of CNS events between the abiraterone acetate cohort and the other cohorts. A sensitivity analysis of patients with a diagnosis of metastasis was also conducted. RESULTS: A total of 1067 patients receiving abiraterone acetate, 5524 receiving bicalutamide, 592 receiving enzalutamide, and 256 receiving chemotherapy were identified. After 12 months, patients who received abiraterone acetate were less likely to have a CNS event than patients who received enzalutamide (39.5% vs 46.0%, respectively; P = .0036) or chemotherapy (39.5% vs 51.1%, respectively; P = .0277), and were more likely to have a CNS event than patients who received bicalutamide (39.5% vs 34.2%, respectively; P = .0397). After multivariate adjustment, at 12 months, patients who initiated abiraterone acetate treatment had 20% (P = .0388) reduction in the risk for a CNS event compared with patients who initiated enzalutamide; 8% (P = .3622) versus bicalutamide; and 27% (P = .0456) versus chemotherapy. The sensitivity analysis yielded similar results. CONCLUSION: The results of this large observational study suggest that among patients with metastatic prostate cancer, treatment with abiraterone acetate is associated with a significantly lower likelihood of having a CNS event compared with treatment with enzalutamide or chemotherapy, but not with bicalutamide, even when controlling for metastatic disease. [ABSTRACT FROM AUTHOR]

Published
2017

171. Shell Swap.

Author

Dawson, Nancy

Subjects
HERMIT crabs, MARINE biology, CLEARINGHOUSES, FOREST litter, TROPICAL forests, SNAIL shells
Abstract

A LITTLE HERMIT crab living in a tropical forest has a big problem. From largest to smallest, each crab slips out of its shell and dives into the shell one size larger. The Secret Lives of Hermit Crabs Hermit crabs range in size from smaller than your thumbnail to bigger than a coconut. [Extracted from the article]

Published
2020

172. A two-part phase 2 randomized study of dalantercept and axitinib versus placebo plus axitinib in advanced renal cell carcinoma: Results from the part 1 dose escalation cohorts.

Author

Atkins, Michael B., primary, Voss, Martin Henner, additional, Plimack, Elizabeth R., additional, Rini, Brian I., additional, Alter, Robert, additional, Dawson, Nancy Ann, additional, Beck, J. Thaddeus, additional, Bhatt, Rupal Satish, additional, Pappas, Kristen M., additional, Wilson, Dawn, additional, McClure, Ty, additional, Kumar, Ravi, additional, Attie, Kenneth M., additional, Sherman, Matthew L., additional, and Pandya, Shuchi Sumant, additional

Published
2014
Full Text
View/download PDF

173. A safety study of cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).

Author

Karzai, Fatima, primary, Shah, Avani Atul, additional, Ojemuyiwa, Michelle A., additional, Madan, Ravi Amrit, additional, Apolo, Andrea Borghese, additional, Dawson, Nancy Ann, additional, Arlen, Philip M., additional, Theoret, Marc Robert, additional, Wright, John Joseph, additional, Chen, Clara, additional, Trepel, Jane B., additional, Couvillon, Anna, additional, Chun, Guinevere, additional, Harold, Nancy, additional, Steinberg, Seth M., additional, Price, Douglas K., additional, Gulley, James L., additional, Figg, William Douglas, additional, and Dahut, William L., additional

Published
2014
Full Text
View/download PDF

176. A phase I study of the multikinase inhibitor cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).

Author

Karzai, Fatima H., primary, Shah, Avani Atul, additional, Ojemuyiwa, Michelle A., additional, Madan, Ravi Amrit, additional, Apolo, Andrea Borghese, additional, Dawson, Nancy Ann, additional, Arlen, Philip M., additional, Theoret, Marc Robert, additional, Wright, John Joseph, additional, Chen, Clara, additional, Trepel, Jane B., additional, Couvillon, Anna, additional, Chun, Guinevere, additional, Harold, Nancy, additional, Steinberg, Seth M., additional, Price, Douglas K., additional, Gulley, James L., additional, Figg, William Douglas, additional, and Dahut, William L., additional

Published
2014
Full Text
View/download PDF

177. A phase II study of cabozantinib in patients (pts) with relapsed or refractory metastatic urothelial carcinoma (mUC).

Author

Apolo, Andrea Borghese, primary, Parnes, Howard L., additional, Madan, Ravi Amrit, additional, Gulley, James L., additional, Wright, John Joseph, additional, Hoffman-Censits, Jean H., additional, Dawson, Nancy Ann, additional, Trepel, Jane B., additional, Khadar, Kattie, additional, Schlom, Jeffrey, additional, Merino, Maria, additional, Raffeld, Mark, additional, Steinberg, Seth M., additional, Choyke, Peter L., additional, Lindenberg, Maria Liza, additional, Folio, Les, additional, Agarwal, Piyush K., additional, Figg, William Douglas, additional, Bottaro, Donald P., additional, and Dahut, William L., additional

Published
2014
Full Text
View/download PDF

180. Improving western United States snow water equivalent (SWE) estimates from passive microwave sensors

Author

Pitter, Shanna, Nolin, Anne, Dawson, Nancy, Cross, Susan, and Rodriguez, Yasmin

Subjects
Colorado, Snowpack telemetry, Pacific Northwest, Spatial estimates, Linear regression, Department of Agriculture
Abstract

The purpose of this research is to improve spatial estimates of snow water equivalent (SWE) from passive microwave sensors. U.S. Department of Agriculture National Resources Conservation Service snowpack telemetry (SNOTEL) data are used as ground truth to improve the western U.S. SWE estimates from the Nimbus-7 Scanning Multichannel Microwave Radiometer (SMMR) and the U.S. Defense Meteorological Satellite Program Special Sensor Microwave/Imager (SSM/I). Predictive models are developed using simple linear regression between the satellite-derived SWE and SWE measured at the SNOTEL stations. The regressions are done using calibration and validation periods from the 1981–1999 water years. The calibration period is used to develop the regression and the validation period is used to test the regression model. The regions studied are the Pacific Northwest and Colorado. The regression equations for each region fit the data with R2 values ranging from .46 to .66, indicating that the models adequately predict observed SWE. The predictive models for Colorado are significantly better than the models developed for the Pacific Northwest. The best model is for Colorado with SMMR data. Differences in the fits of the models suggest regional differences in the data. When vegetation cover is examined, the Pacific Northwest exhibits a much higher percent tree cover than the Colorado region. Correlations between mean vegetation cover and maximum microwave SWE are negative, ranging from –0.32 to -0.63 for the Pacific Northwest, while in Colorado, the correlations are statistically insignificant. This suggests that vegetation impacts the accuracy of satellite-derived SWE.

Published
2001
Full Text
View/download PDF

181. SOARS Earth, Wind, Sea, and Sky: Protégé Abstracts 2001

Author

Dawson, Nancy, Windham, Thomas, Calvin, Carlye, Pagel, Wendy, Church, Andrew, Datulayta, Pauline, Dollen, Kate, Hudman, Rynda, Johnson, Michael Ray, Johnson, Theresa Jo, Kelly, Resa M., Martinez, Maribel, Muñoz-Acevedo, Ernesto, Navarro, Bradley C., Navarro, Fabiola, Noble, Erik Ulysses, Pitter, Shanna T.L., Rivera, Monica, Rodriguez, Yarice, Rodriguez, Yasmin, Sands, Jaclyn Summer, Singleton, Tamara, Tessendorf, Sarah, Thornbrugh, Casey C., and Walford, Segayle C.

Subjects
Science--Study and teaching
Published
2001
Full Text
View/download PDF

182. A randomized phase II trial of sipuleucel-T with concurrent or sequential abiraterone acetate (AA) plus prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).

Author

Small, Eric Jay, primary, Lance, Raymond S., additional, Redfern, Charles H., additional, Millard, Frederick E., additional, Gardner, Thomas A., additional, Karsh, Lawrence Ivan, additional, Dawson, Nancy Ann, additional, McCoy, Candice, additional, Stubbs, Andrew, additional, DeVries, Todd, additional, dela Rosa, Corazon P., additional, Sheikh, Nadeem A., additional, and Shore, Neal D., additional

Published
2013
Full Text
View/download PDF

183. Use of supportive measures to improve outcome and decrease toxicity in docetaxel-based antiangiogenesis combinations in metastatic castrate resistant prostate cancer (mCRPC).

Author

Karzai, Fatima H., primary, Madan, Ravi Amrit, additional, Apolo, Andrea Borghese, additional, Ning, Yangmin M., additional, Parnes, Howard L., additional, Arlen, Philip M., additional, Beatson, Melony A., additional, Harold, Nancy, additional, Couvillon, Anna, additional, Wright, John Joseph, additional, Chen, Clara, additional, Dawson, Nancy Ann, additional, Gulley, James L., additional, Figg, William Douglas, additional, and Dahut, William L., additional

Published
2013
Full Text
View/download PDF

184. Intermittent versus Continuous Androgen Deprivation in Prostate Cancer

Author

Hussain, Maha, primary, Tangen, Catherine M., additional, Berry, Donna L., additional, Higano, Celestia S., additional, Crawford, E. David, additional, Liu, Glenn, additional, Wilding, George, additional, Prescott, Stephen, additional, Kanaga Sundaram, Subramanian, additional, Small, Eric Jay, additional, Dawson, Nancy Ann, additional, Donnelly, Bryan J., additional, Venner, Peter M., additional, Vaishampayan, Ulka N., additional, Schellhammer, Paul F., additional, Quinn, David I., additional, Raghavan, Derek, additional, Ely, Benjamin, additional, Moinpour, Carol M., additional, Vogelzang, Nicholas J., additional, and Thompson, Ian M., additional

Published
2013
Full Text
View/download PDF

185. Stereotactic Body Radiation Therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience

Author

Chen, Leonard N, primary, Suy, Simeng, additional, Uhm, Sunghae, additional, Oermann, Eric K, additional, Ju, Andrew W, additional, Chen, Viola, additional, Hanscom, Heather N, additional, Laing, Sarah, additional, Kim, Joy S, additional, Lei, Siyuan, additional, Batipps, Gerald P, additional, Kowalczyk, Keith, additional, Bandi, Gaurav, additional, Pahira, John, additional, McGeagh, Kevin G, additional, Collins, Brian T, additional, Krishnan, Pranay, additional, Dawson, Nancy A, additional, Taylor, Kathryn L, additional, Dritschilo, Anatoly, additional, Lynch, John H, additional, and Collins, Sean P, additional

Published
2013
Full Text
View/download PDF

186. Rationale for Stereotactic Body Radiation Therapy in Treating Patients with Oligometastatic Hormone-Naïve Prostate Cancer

Author

Bhattasali, Onita, primary, Chen, Leonard N., additional, Tong, Michael, additional, Lei, Siyuan, additional, Collins, Brian T., additional, Krishnan, Pranay, additional, Kalhorn, Christopher, additional, Lynch, John H., additional, Suy, Simeng, additional, Dritschilo, Anatoly, additional, Dawson, Nancy A., additional, and Collins, Sean P., additional

Published
2013
Full Text
View/download PDF

188. The use of passive visual stimuli to enhance compliance with handwashing in a perioperative setting.

Author

Beyfus, Tammy A., Dawson, Nancy L., Danner, Cynthia H., Rawal, Bhupendra, Gruber, Paul E., and Petrou, Steven P.

Abstract

Background To encourage handwashing, we analyzed the effect that a passive visual stimulus in the form of a picture of a set of eyes had on self-directed hand hygiene among health care staff. Methods This was a prospective, single-blind study using a repeated measure design. Four dispensers of alcohol foam located in positions identified as #1, #2, #3, and #4 were used to deliver a single uniform volume of alcohol foam in an automated fashion. Pictures of eyes were placed on dispensers #1 and #3 but not dispensers #2 and #4 for 1 time period. The visual stimulus was rotated with each study time period. At the end of each study period, the volumes dispensed were examined to determine if the visual stimulus had a statistically significant influence on the volume dispensed. Results There were a total of 6 time periods. The average volume dispensed in stations with eyes was 279 cc versus that in the stations without eyes, which was 246 cc, and this was a statistically significant difference ( P  = .009). Conclusion The correct visual stimuli may enhance compliance with hand hygiene in health care settings. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

190. Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): Results of S9346 (INT-0162), an international phase III trial.

Author

Hussain, Maha, primary, Tangen, Catherine M., additional, Higano, Celestia S., additional, Crawford, E. David, additional, Liu, Glenn, additional, Wilding, George, additional, Prescott, Stephen, additional, Akdas, Atif, additional, Small, Eric Jay, additional, Dawson, Nancy Ann, additional, Donnelly, Bryan J, additional, Venner, Peter, additional, Vaishampayan, Ulka N., additional, Schellhammer, Paul F., additional, Quinn, David I., additional, Raghavan, Derek, additional, Vogelzang, Nicholas J., additional, and Thompson, Ian Murchie, additional

Published
2012
Full Text
View/download PDF

191. Dual antiangiogenic therapy using lenalidomide and bevacizumab with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).

Author

Adesunloye, Bamidele, primary, Huang, Xuan, additional, Ning, Yangmin M., additional, Madan, Ravi A., additional, Gulley, James L., additional, Beatson, Melony, additional, Kluetz, Paul Gustav, additional, Adelberg, David E., additional, Arlen, Philip M., additional, Parnes, Howard L., additional, Mulquin, Marcia, additional, Steinberg, Seth M., additional, Wright, John Joseph, additional, Trepel, Jane B., additional, Dawson, Nancy Ann, additional, Chen, Clara, additional, Bassim, Carol, additional, Apolo, Andrea Borghese, additional, Figg, William Douglas, additional, and Dahut, William L., additional

Published
2012
Full Text
View/download PDF

192. Phase II trial of bevacizumab and lenalidomide with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).

Author

Adesunloye, Bamidele, primary, Huang, Xuan, additional, Ning, Yangmin M., additional, Madan, Ravi A., additional, Gulley, James L., additional, Beatson, Melony, additional, Kluetz, Paul Gustav, additional, Adelberg, David, additional, Arlen, Philip M., additional, Parnes, Howard L., additional, Mulquin, Marcia, additional, Steinberg, Seth M., additional, Wright, John Joseph, additional, Trepel, Jane B., additional, Dawson, Nancy Ann, additional, Chen, Clara, additional, Apolo, Andrea Borghese, additional, Figg, William Douglas, additional, and Dahut, William L., additional

Published
2012
Full Text
View/download PDF

194. A Phase II Clinical Trial of TRC105 (Anti-Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial Carcinoma

Author

Apolo, Andrea B., Karzai, Fatima H., Trepel, Jane B., Alarcon, Sylvia, Lee, Sunmin, Lee, Min-Jung, Tomita, Yusuke, Cao, Liang, Yu, Yunkai, Merino, Maria J., Madan, Ravi A., Parnes, Howard L., Steinberg, Seth M., Rodriguez, Beatriz Walter, Seon, Ben K., Gulley, James L., Arlen, Philip M., Dawson, Nancy A., Figg, William D., and Dahut, William L.

Abstract

TRC105 is a chimeric monoclonal antibody that targets CD105 (endoglin). Heavily pretreated patients with metastatic urothelial carcinoma received TRC105 at 15 mg/m2every 2 weeks on a 28-day cycle. Treatment was not associated with significant toxicities, but did not improve 6-month progression-free survival. Exploratory analyses suggest interplay between immunosuppressive subsets and TRC105, which warrants further study.

Published
2017
Full Text
View/download PDF

195. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

Author

Balar, Arjun V, Galsky, Matthew D, Rosenberg, Jonathan E, Powles, Thomas, Petrylak, Daniel P, Bellmunt, Joaquim, Loriot, Yohann, Necchi, Andrea, Hoffman-Censits, Jean, Perez-Gracia, Jose Luis, Dawson, Nancy A, van der Heijden, Michiel S, Dreicer, Robert, Srinivas, Sandy, Retz, Margitta M, Joseph, Richard W, Drakaki, Alexandra, Vaishampayan, Ulka N, Sridhar, Srikala S, Quinn, David I, Durán, Ignacio, Shaffer, David R, Eigl, Bernhard J, Grivas, Petros D, Yu, Evan Y, Li, Shi, Kadel, Edward E, Boyd, Zachary, Bourgon, Richard, Hegde, Priti S, Mariathasan, Sanjeev, Thåström, AnnChristine, Abidoye, Oyewale O, Fine, Gregg D, and Bajorin, Dean F

Abstract

First-line chemotherapy for patients with cisplatin-ineligible locally advanced or metastatic urothelial carcinoma is associated with short response duration, poor survival, and high toxicity. This study assessed atezolizumab (anti-programmed death-ligand 1 [PD-L1]) as treatment for metastatic urothelial cancer in cisplatin-ineligible patients.

Published
2017
Full Text
View/download PDF

196. Patient Perception of Physician Attire Before and After the COVID-19 Global Pandemic Began

Author

Hedges, Mary S., Tolaymat, Leila M., Haskell, Nicole K., Prier, Cara, Walker, Ashley L., Haga, Claire, Li, Zhuo, Yin, Mingyuan, McManus, Mindy, and Dawson, Nancy

Abstract

Introduction:This study evaluated patient preference of physician attire both before and after the coronavirus disease 2019 (COVID-19) global pandemic began. The primary outcome was patient preference of physician attire in 2017 compared to 2022 survey cohorts. Methods:An observational cross-sectional study performed at a single-site academic institution in the United States using patient survey materials. In total, 339 patients were included in the study, 161 from 2017 and 178 from 2022. Key Points:There was a statistically significant decrease in patient preference for formal attire in the clinical settings of primary care, hospital, and overall. Male patient preference for formal attire declined in primary care, emergency room, and overall; whereas female patient preference for formal attire declined in the hospital setting. For all genders, the odds ratio was statistically significantly lower in the settings of primary care clinic, hospital, and overall clinical settings. Conclusions:Patient preference for physicians wearing formal attire has decreased significantly since the COVID-19 global pandemic began.

Published
2023
Full Text
View/download PDF

200. Adjuvant Androgen Deprivation for High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921 Study

Author

Dorff, Tanya B., primary, Flaig, Thomas W., additional, Tangen, Catherine M., additional, Hussain, Maha H.A., additional, Swanson, Gregory P., additional, Wood, David P., additional, Sakr, Wael A., additional, Dawson, Nancy A., additional, Haas, Naomi B., additional, Crawford, E. David, additional, Vogelzang, Nicholas J., additional, Thompson, Ian M., additional, and Glode, L. Michael, additional

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results